The latest on GLP-1s, metabolic health and the future of employer healthcare.

GLP-1 management should not stop at eligibility. Regular clinical evaluation can help employers support participants who are benefiting while identifying when treatment needs to be reassessed.

The most useful GLP-1 ROI models aren't the ones with the biggest projected return. They're the ones built on transparent assumptions, measurable inputs, and realistic expectations that employers can explain with confidence.

As more employers evaluate GLP-1 coverage, the conversation is shifting beyond drug costs. Learn why adherence, clinical oversight, and program design are becoming central to successful employer GLP-1 strategies.

Chronic conditions affect more than healthcare spending. As chronic disease becomes increasingly common among working-age adults, employers are facing growing challenges related to productivity, absenteeism, workforce engagement, and long-term healthcare costs.

While weight loss remains an important outcome, healthcare providers are increasingly recognizing that weight alone does not tell the full story. Body composition, metabolic health, physical function, and long-term sustainability are becoming important considerations alongside weight loss outcomes.

Insights from the eMed Health Innovation Revolution Summit on chronic disease prevention, engagement, and long-term health outcomes

Building a sustainable fitness routine does not require perfection or extreme workouts. Learn how flexibility, consistency, and realistic habits can support long-term health and wellbeing.

Many workplace wellness challenges create short-term motivation but fail to support lasting behavior change. Explore why sustainable employee health requires consistency, accountability, and long-term support.

Metabolic health has become a central topic in conversations about chronic disease, healthcare costs, and long-term outcomes.

As GLP-1 utilization increases, low adherence and inconsistent treatment management are driving higher employer healthcare costs and variable outcomes.

Employers are investing in preventive care and GLP-1 medications, but inconsistent utilization and high discontinuation rates are limiting outcomes and increasing long-term costs.

Early-year engagement fades by April, revealing which employee health behaviors persist and which drive long-term healthcare costs.

GLP-1 medications are redefining obesity treatment by addressing the biological drivers of metabolic disease and long-term weight management.

Small nutrition habits can influence long term health more than short term diets. Discover 10 practical habits that support balanced nutrition and sustainable eating patterns.

GLP-1 medications are reshaping obesity treatment, metabolic health, and healthcare economics. Why GLP-1s represent a true market reset.

Millions could benefit from GLP-1 medications but face barriers like cost, coverage, and provider shortages. Why access will define the next phase.